Cargando…
Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment
We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1–4 of the COSYCONET cohort with follow-up data of up to 4.5 y were include...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792053/ https://www.ncbi.nlm.nih.gov/pubmed/35082306 http://dx.doi.org/10.1038/s41598-022-05276-x |
_version_ | 1784640324335828992 |
---|---|
author | Kahnert, Kathrin Andreas, Stefan Kellerer, Christina Lutter, Johanna I. Lucke, Tanja Yildirim, Önder Lehmann, Mareike Seissler, Jochen Behr, Jürgen Frankenberger, Marion Bals, Robert Watz, Henrik Welte, Tobias Trudzinski, Franziska C. Vogelmeier, Claus F. Alter, Peter Jörres, Rudolf A. |
author_facet | Kahnert, Kathrin Andreas, Stefan Kellerer, Christina Lutter, Johanna I. Lucke, Tanja Yildirim, Önder Lehmann, Mareike Seissler, Jochen Behr, Jürgen Frankenberger, Marion Bals, Robert Watz, Henrik Welte, Tobias Trudzinski, Franziska C. Vogelmeier, Claus F. Alter, Peter Jörres, Rudolf A. |
author_sort | Kahnert, Kathrin |
collection | PubMed |
description | We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1–4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV(1), FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively; p < 0.05 each), but not the decline of FEV(1) and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema. |
format | Online Article Text |
id | pubmed-8792053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87920532022-01-28 Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment Kahnert, Kathrin Andreas, Stefan Kellerer, Christina Lutter, Johanna I. Lucke, Tanja Yildirim, Önder Lehmann, Mareike Seissler, Jochen Behr, Jürgen Frankenberger, Marion Bals, Robert Watz, Henrik Welte, Tobias Trudzinski, Franziska C. Vogelmeier, Claus F. Alter, Peter Jörres, Rudolf A. Sci Rep Article We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1–4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV(1), FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin. Among 2741 patients, 1541 (mean age 64.4 y, 601 female) fulfilled the inclusion criteria. In the group with metformin treatment vs. non-diabetes the mean annual decline in KCO and TLCO was significantly lower (0.2 vs 2.3, 0.8 vs. 2.8%predicted, respectively; p < 0.05 each), but not the decline of FEV(1) and FVC. These results were confirmed using multiple regression and propensity score analyses. Our findings demonstrate an association between the annual decline of lung diffusing capacity and the intake of metformin in patients with COPD consistent with the hypothesis of anti-aging effects of metformin as reflected in a surrogate marker of emphysema. Nature Publishing Group UK 2022-01-26 /pmc/articles/PMC8792053/ /pubmed/35082306 http://dx.doi.org/10.1038/s41598-022-05276-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kahnert, Kathrin Andreas, Stefan Kellerer, Christina Lutter, Johanna I. Lucke, Tanja Yildirim, Önder Lehmann, Mareike Seissler, Jochen Behr, Jürgen Frankenberger, Marion Bals, Robert Watz, Henrik Welte, Tobias Trudzinski, Franziska C. Vogelmeier, Claus F. Alter, Peter Jörres, Rudolf A. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title_full | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title_fullStr | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title_full_unstemmed | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title_short | Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment |
title_sort | reduced decline of lung diffusing capacity in copd patients with diabetes and metformin treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792053/ https://www.ncbi.nlm.nih.gov/pubmed/35082306 http://dx.doi.org/10.1038/s41598-022-05276-x |
work_keys_str_mv | AT kahnertkathrin reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT andreasstefan reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT kellererchristina reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT lutterjohannai reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT lucketanja reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT yildirimonder reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT lehmannmareike reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT seisslerjochen reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT behrjurgen reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT frankenbergermarion reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT balsrobert reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT watzhenrik reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT weltetobias reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT trudzinskifranziskac reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT vogelmeierclausf reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT alterpeter reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT jorresrudolfa reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment AT reduceddeclineoflungdiffusingcapacityincopdpatientswithdiabetesandmetformintreatment |